Portal de Periódicos da CAPES

Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies

2010; Elsevier BV; Volume: 115; Issue: 22 Linguagem: Inglês

10.1182/blood-2009-07-232504

1528-0020

Jasmine C. Wong, Yan Zhang, Kenneth Lieuw, Mary Tran, Erna Forgó, Kelley Weinfurtner, Pilar Alzamora, Scott C. Kogan, Keiko Akagi, Linda Wolff, Michelle M. Le Beau, Nigel Killeen, Kevin Shannon,

Lymphoma Diagnosis and Treatment

Abstract Monosomy 7 and del(7q) are associated with adverse features in myeloid malignancies. A 2.5-Mb commonly deleted segment (CDS) of chromosome band 7q22 is implicated as harboring a myeloid tumor suppressor gene (TSG); however, molecular analysis of candidate TSGs has not uncovered loss of function. To determine whether haploinsufficiency for the 7q22 CDS contributes to myeloid leukemogenesis, we performed sequential gene targeting to flank a region of orthologous synteny on mouse chromosome band 5A3 with loxP sites. We then generated Mx1-Cre, 5A3fl mutant mice and deleted the targeted interval in vivo. Although excision was inefficient, we confirmed somatic deletion of the 5A3 CDS in the hematopoietic stem cell compartment. Mx1-Cre, 5A3fl mice show normal hematologic parameters and do not spontaneously develop myeloid malignancies. The 5A3fl deletion does not cooperate with oncogenic KrasG12D expression, Nf1 inactivation, or retroviral mutagenesis to accelerate leukemia development and did not modulate responsiveness to antileukemia drugs. These studies demonstrate that it is feasible to somatically delete a large chromosomal segment implicated in tumor suppression in hematopoietic cell populations in vivo; however, our data do not support the hypothesis that the 7q22/5A3 CDS interval contains a myeloid TSG.